Capital Fund Management (CFM)
RXRX icon

Capital Fund Management (CFM)’s Recursion Pharmaceuticals RXRX Stock Holding History

Capital Fund Management (CFM)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.86M Buy
1,909,480
+130,504
+7% +$504K 0.03% 815
2025
Q4 		$7.28M Buy
1,778,976
+1,052,952
+145% +$5.22M 0.02% 989
2025
Q3 		$3.54M Buy
726,024
+5,498
+0.8% +$28.9K 0.01% 1454
2025
Q2 		$3.65M Buy
720,526
+513,258
+248% +$2.52M 0.01% 1341
2025
Q1 		$1.1M Buy
207,268
+23,472
+13% +$171K ﹤0.01% 1639
2024
Q4 		$1.24M Buy
+183,796
New +$1.24M ﹤0.01% 1690

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Fund Management (CFM)'s RXRX Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Recursion Pharmaceuticals (RXRX) stake by 7.3% in Q1 2026, buying an estimated $504K and bringing the position to 1,909,480 shares worth $5.86M. The position accounts for 0.03% of the portfolio, ranked #815.

Capital Fund Management (CFM) first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.28M in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Capital Fund Management (CFM) held 1,909,480 shares of Recursion Pharmaceuticals worth $5.86M as of Q1 2026.
  • Capital Fund Management (CFM) bought 130,504 Recursion Pharmaceuticals shares in Q1 2026, an estimated $504K.
  • Recursion Pharmaceuticals made up 0.03% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #815 holding.
  • Capital Fund Management (CFM) first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Capital Fund Management (CFM)'s Recursion Pharmaceuticals position peaked at $7.28M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.